Early effects of brain death on kidney injury and outcome after transplantation

). Groups were tested for normal distribution using the One-Sample Kolmogorov-Smirnov Test. Results are expressed as arithmetic means ± standard error of the mean. To investigate differences in kidney function during IPK, AUCs (area under the curve) for creatinine clearance were calculated. Statistical comparisons between unpaired groups were performed using ANOVA. All differences were considered to be significant at P<0.05.

[1]  K. Eckardt,et al.  Activation of hypoxia-inducible factors ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  Claude D Martin,et al.  Impact of intensive care on renal function before graft harvest: results of a monocentric study , 2007, Critical care.

[3]  R. Ploeg,et al.  The gradual onset brain death model: a relevant model to study organ donation and its consequences on the outcome after transplantation , 2007, Laboratory animals.

[4]  N. Ichimaru,et al.  Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimulating erythropoiesis. , 2007, Biochemical and biophysical research communications.

[5]  D. Holtzman,et al.  Cell Death Mechanism and Protective Effect of Erythropoietin after Focal Ischemia in the Whisker-Barrel Cortex of Neonatal Rats , 2006, Journal of Pharmacology and Experimental Therapeutics.

[6]  Z. Erbayraktar,et al.  Carbamylated Erythropoietin Reduces Radiosurgically-Induced Brain Injury , 2006, Molecular medicine.

[7]  W. Miller,et al.  Astroglial cytoprotection by erythropoietin pre‐conditioning: implications for ischemic and degenerative CNS disorders , 2005, Journal of neurochemistry.

[8]  P. Ghezzi,et al.  A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Ploeg,et al.  Effect of Brain Death on Gene Expression and Tissue Activation in Human Donor Kidneys , 2004, Transplantation.

[10]  P. Ghezzi,et al.  Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Sánchez-Fructuoso,et al.  Does Donor Brain Death Influence Acute Vascular Rejection in the Kidney Transplant? , 2004, Transplantation.

[12]  Z. Erbayraktar,et al.  Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.

[13]  H. van Goor,et al.  Effect of brain death and non-heart-beating kidney donation on renal function and injury: an assessment in the isolated perfused rat kidney. , 2003, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[14]  G. Molema,et al.  Relationship between duration of brain death and hemodynamic (in)stability on progressive dysfunction and increased immunologic activation of donor kidneys. , 2003, Kidney international.

[15]  Richard B. Thompson,et al.  A novel protective effect of erythropoietin in the infarcted heart. , 2003, The Journal of clinical investigation.

[16]  P. Ghezzi,et al.  Erythropoietin Selectively Attenuates Cytokine Production and Inflammation in Cerebral Ischemia by Targeting Neuronal Apoptosis , 2003, The Journal of experimental medicine.

[17]  Chul-woo Yang,et al.  Preconditioning with erythropoietin protects against subsequent ischemia‐reperfusion injury in rat kidney , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  I. Doxiadis,et al.  The superior results of living-donor renal transplantation are not completely caused by selection or short cold ischemia time: a single-center, multivariate analysis , 2003, Transplantation.

[19]  K. Maiese,et al.  Erythropoietin: cytoprotection in vascular and neuronal cells. , 2003, Current drug targets. Cardiovascular & haematological disorders.

[20]  R. Sasaki.  Pleiotropic functions of erythropoietin. , 2003, Internal medicine.

[21]  P. Ghezzi,et al.  Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis , 2002, Brain Research.

[22]  M. Wilhelm,et al.  Activation of inflammatory mediators in rat renal isografts by donor brain death. , 2000, Transplantation.

[23]  D. Dunn,et al.  Immunologic and nonimmunologic factors: different risks for cadaver and living donor transplantation. , 2000, Transplantation.

[24]  N. Vaziri,et al.  Mechanism of erythropoietin-induced hypertension. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  D. Novitzky,et al.  Detrimental effects of brain death on the potential organ donor. , 1997, Transplantation proceedings.

[26]  E. Borda,et al.  Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: Signal transduction pathways , 1996, Journal of cellular physiology.

[27]  T. Akizawa,et al.  rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells. , 1996, Kidney international.

[28]  S Takemoto,et al.  High survival rates of kidney transplants from spousal and living unrelated donors. , 1995, The New England journal of medicine.

[29]  D. Dunn,et al.  Successful long-term outcome with 0-haplotype-matched living-related kidney donors , 1994, Pediatric Nephrology.

[30]  J. Spivak.  The clinical physiology of erythropoietin. , 1993, Seminars in hematology.

[31]  W. Wicomb,et al.  The pathophysiological effects of brain death on potential donor organs, with particular reference to the heart. , 1989, Annals of the Royal College of Surgeons of England.

[32]  J. Benach,et al.  Interleukin 1: a common endogenous mediator of inflammation and the local Shwartzman reaction. , 1986, Journal of immunology.

[33]  J. Brosnan,et al.  Improved function with amino acids in the isolated perfused kidney. , 1982, The American journal of physiology.

[34]  G. R. Hervey.  Determination of Creatinine by the Jaffé Reaction , 1953, Nature.

[35]  B. Sela.  [Selectins: vascular adhesion molecules]. , 2000, Harefuah.

[36]  T. Hirano.  Interleukin-6 and its relation to inflammation and disease. , 1992, Clinical immunology and immunopathology.

[37]  H. Bergmeyer,et al.  Optimization of methods for aspartate aminotransferase and alanine aminotransferase. , 1978, Clinical chemistry.